Gestational trophoblastic neoplasia treatment at the Butaro Cancer Center of Excellence in Rwanda

Nzayisenga, I; Segal, R; Pritchett, N; Xu, MJ; Park, PH; Mpanumusingo, EV; Umuhizi, DG; Goldstein, DP; Berkowitz, RS; Hategekimana, V; Muhayimana, C; Rubagumya, F; Fadelu, T; Tapela, N; Mpunga, T; Ghebre, RG

Journal article

Gestational trophoblastic neoplasia treatment at the Butaro Cancer Center of Excellence in Rwanda

Abstract:: Purpose
Gestational trophoblastic neoplasia (GTN) is a highly treatable disease, most often affecting young women of childbearing age. This study reviewed patients managed for GTN at the Butaro Cancer Center of Excellence (BCCOE) in Rwanda to determine initial program outcomes.
Patients and Methods
A retrospective medical record review was performed for 35 patients with GTN assessed or treated between May 1, 2012, and November 30, 2014. Stage, risk score, and low or high GTN risk category were based on International Federation of Gynecology and Obstetrics staging and the WHO scoring system and determined by beta human chorionic gonadotropin level, chest x-ray, and ultrasound per protocol guidelines for resource-limited settings. Pathology reports and computed tomography scans were assessed when possible. Treatment was based on a predetermined protocol stratified by risk status.
Results
Of the 35 patients (mean age, 32 years), 26 (74%) had high-risk and nine (26%) had low-risk disease. Nineteen patients (54%) had undergone dilation and curettage and 11 (31%) had undergone hysterectomy before evaluation at BCCOE. Pathology reports were available in 48% of the molar pregnancy surgical cases. Systemic chemotherapy was initiated in 30 of the initial 35 patients: 13 (43%) received single-agent oral methotrexate, 15 (50%) received EMACO (etoposide, methotrexate, dactinomycin, cyclophosphamide, and vincristine), and two (7%) received alternate regimens. Of the 13 patients initiating methotrexate, three had their treatment intensified to EMACO. Four patients experienced treatment delays because of medication stockouts. At a median follow-up of 7.8 months, the survival probability for low-risk patients was 1.00; for high-risk patients, it was 0.63.
Conclusion
This experience demonstrates the feasibility of GTN treatment in rural, resource-limited settings. GTN is a curable disease and can be treated following the BCCOE model of cancer care.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Nzayisenga, I., Segal, R., Pritchett, N., Xu, M. J., Park, P. H., Mpanumusingo, E. V., Umuhizi, D. G., Goldstein, D. P., Berkowitz, R. S., Hategekimana, V., Muhayimana, C., Rubagumya, F., Fadelu, T., Tapela, N., Mpunga, T., & Ghebre, R. G. (2016). Gestational trophoblastic neoplasia treatment at the Butaro Cancer Center of Excellence in Rwanda. Journal of Global Oncology, 2(6), 365–374.

MLA Style

Nzayisenga, I., et al. “Gestational Trophoblastic Neoplasia Treatment at the Butaro Cancer Center of Excellence in Rwanda.” Journal of Global Oncology, vol. 2, no. 6, American Society of Clinical Oncology, 2016, pp. 365–74.

Chicago Style

Nzayisenga, I, R Segal, N Pritchett, MJ Xu, PH Park, EV Mpanumusingo, DG Umuhizi, et al. 2016. “Gestational Trophoblastic Neoplasia Treatment at the Butaro Cancer Center of Excellence in Rwanda.” Journal of Global Oncology 2 (6): 365–74.
Share
Print